As an anterior extension of the central nervous system, the eye provides a unique, non-invasive potential “window to the brain” to screen and diagnose early Alzheimer’s disease (AD), which is critical for the successful evaluation of new treatments and the discovery of novel therapeutic targets. We aim to identify a novel combinatorial biomarker for early Alzheimer’s disease based on retinal visual and functional changes detected using noninvasive novel ophthalmic imaging modalities combined with deep learning analysis. By simultaneously evaluating many promising biomarkers in patients who are cognitively normal compared to those who have mild cognitive impairment or early AD, we seek to identify the panel of biomarker tests that are diagnostic of early Alzheimer’s disease and/or predictive of AD development.